Related Experiment Videos
Transcriptomic analysis of the NCI-60 cancer cell lines
John N Weinstein1, Yves Pommier
1Laboratory of Molecular Pharmacology, Center for Cancer Research, US National Cancer Institute, NIH, Department of Health and Human Services, 9000 Rockville Pike, Bethesda, MD 20892, USA. jw4i@nih.gov
Abstract:
Pharmacogenomics aims at molecular subsetting of patients for more effective therapy. Transcriptomic profiling of the 60 human cancer cell lines (the NCI-60) used by the US National Cancer Institute serves that aim because the cells have been treated with > 100,000 chemical compounds over the last 13 years. Patterns of potency can be mapped into molecular structures of the compounds or into molecular characteristics of the cells. We discuss conceptual and experimental aspects of the profiling, as well as a number of bioinformatic computer programs that we have developed for biological interpretation of the profiles.
Insights
Pharmacogenomics uses transcriptomic profiling of cancer cell lines to discover effective cancer therapies. By analyzing drug potency patterns, researchers can map compound structures to cellular characteristics for personalized medicine.
Area of Science:
- Genomics
- Pharmacology
- Bioinformatics
Background:
- Pharmacogenomics seeks to tailor medical treatments to individual patients based on their genetic makeup.
- The National Cancer Institute's 60 human cancer cell lines (NCI-60) have been exposed to over 100,000 chemical compounds.
- This extensive dataset provides a unique resource for understanding drug response.
Purpose of the Study:
- To explore the utility of transcriptomic profiling of the NCI-60 cell lines for pharmacogenomic drug discovery.
- To establish methods for mapping drug potency patterns to molecular features of compounds and cells.
- To present bioinformatic tools developed for interpreting these complex biological profiles.
Main Methods:
- Transcriptomic profiling of the NCI-60 cancer cell line panel.
- Treatment of cell lines with a large library of chemical compounds.
- Analysis of drug potency across diverse cell lines.
- Bioinformatic analysis to correlate drug effects with molecular characteristics.
Main Results:
- Identification of patterns linking drug potency to specific molecular features of compounds and cancer cells.
- Demonstration of the feasibility of using the NCI-60 as a model system for pharmacogenomic studies.
- Development of computational tools to aid in the biological interpretation of profiling data.
Conclusions:
- Transcriptomic profiling of the NCI-60 is a valuable approach for advancing pharmacogenomics and identifying potential cancer therapeutics.
- Mapping drug response patterns can guide the development of more effective and personalized cancer treatments.
- The developed bioinformatic programs facilitate the biological interpretation of large-scale drug screening data.